Quest Diagnostics (NYSE: DGX) reported second-quarter financial results before the regular market hours on Thursday. The Q2 earnings were a cent higher than the average Wall Street prediction, while the revenues were in line.
DGX shares fell 1.8% immediately following the announcement. The stock has gained 23% since the beginning of the year.
CEO Steve Rusckowski said, “Looking forward to the rest of the year, we will continue to expand COVID-19 testing capacity while also continuing to serve our customers as they continue to recover from the pandemic.”
Prior performance
[irp posts=”66899″]